Chronic Pulmonary Hypertension Market

• Chronic Pulmonary Hypertension Prevalence is expected to rise, driven by aging populations, obesity trends, improved premature infant survival, environmental factors, genetic predisposition, enhanced diagnostics, and rising comorbidities.
• In 2023, the US accounted for the maximum diagnosed patient share of Chronic Pulmonary Hypertension in the 7MM, i.e., 42%, followed by Japan accounting for around 16% of the total 7MM cases. Among the European countries higher number of cases were in the UK accounting for about 11% of the total 7MM cases.
• In 2023, the Chronic Pulmonary Hypertension Market Size was highest in the US among the 7MM accounting for approximately USD 15,700 million that is further expected to increase by 2034.
• Despite of high prevalence with total cases of around 42,476 thousand in 2023 in the 7MM, the treatment market of Chronic Pulmonary Hypertension has less therapies specific to Chronic Pulmonary Hypertension treatment.
• Emerging therapies have the potential to create a significant positive shift in the Chronic Pulmonary Hypertension Market Size.

Request for unlocking the sample page of the "Chronic Pulmonary Hypertension Treatment Market"

DelveInsight's “Chronic Pulmonary Hypertension Market Insights, Epidemiology and Market Forecast– 2034” report delivers an in-depth understanding of the Chronic Pulmonary Hypertension, historical and forecasted epidemiology as well as the Chronic Pulmonary Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Chronic Pulmonary Hypertension Treatment Market Report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Chronic Pulmonary Hypertension market size from 2020 to 2034. The Chronic Pulmonary Hypertension drugs market report also covers current Chronic Pulmonary Hypertension treatment market practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Chronic Pulmonary Hypertension Disease Treatment Market: Understanding and Algorithm

Chronic pulmonary hypertension is a condition marked by elevated blood pressure in the lungs, leading to strain on the heart and potentially life-threatening symptoms like shortness of breath and fatigue. The classification includes five groups: Group 1 comprises pulmonary arterial hypertension (PAH), Group 2 involves pulmonary hypertension due to left heart disease, Group 3 consists of pulmonary hypertension due to lung diseases and/or hypoxia, Group 4 entails chronic thromboembolic pulmonary hypertension (CTEPH), and Group 5 encompasses pulmonary hypertension with unclear multifactorial mechanisms. Early diagnosis and appropriate management are vital for improving outcomes and quality of life.

Chronic Pulmonary Hypertension Diagnosis

Diagnosing chronic pulmonary hypertension involves a combination of clinical evaluation, imaging studies, and specialized tests. Challenges may arise due to the nonspecific nature of symptoms and the need for distinguishing PH from other cardiovascular and respiratory conditions. Diagnostic procedures include echocardiography to assess heart function and estimate pulmonary artery pressure, followed by confirmatory tests such as right heart catheterization, which directly measures pressures in the pulmonary arteries. Challenges may arise in interpreting results accurately, particularly in cases where other heart or lung conditions coexist, necessitating careful differential diagnosis.

Additionally, identifying the underlying cause of pulmonary hypertension is crucial for appropriate treatment. This may require further investigations such as ventilation-perfusion (V/Q) scans for suspected chronic thromboembolic pulmonary hypertension (CTEPH) or comprehensive assessment for associated conditions like connective tissue diseases. Collaboration among specialists, including cardiologists, pulmonologists, and radiologists, is essential for navigating these diagnostic challenges and ensuring timely and accurate management of chronic pulmonary hypertension.

Further details related to country-based variations are provided in the report...

Chronic Pulmonary Hypertension Treatment

Treating chronic pulmonary hypertension involves a multidisciplinary approach aimed at alleviating symptoms, improving quality of life, and addressing underlying causes. Challenges arise due to the progressive nature of the disease and the complexity of managing associated comorbidities. Therapeutic options include vasodilator medications to relax blood vessels in the lungs, such as calcium channel blockers, endothelin receptor antagonists, prostacyclin analogs, and phosphodiesterase-5 inhibitors. However, selecting the appropriate medication and dosage can be challenging due to individual patient responses and potential adverse effects.

In severe cases or when medication therapy is insufficient, interventions like balloon pulmonary angioplasty or lung transplantation may be considered. However, these options come with their own set of challenges, including limited availability of donor organs and risks associated with surgery. Moreover, managing chronic pulmonary hypertension requires ongoing monitoring and adjustment of treatment plans to address disease progression and optimize outcomes. Close collaboration among healthcare providers, including cardiologists, pulmonologists, and specialized PH centers, is essential for navigating treatment challenges and providing comprehensive care to individuals with chronic pulmonary hypertension.

Chronic Pulmonary Hypertension Epidemiology

As the market is derived using the patient-based model, the Chronic Pulmonary Hypertension epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Prevalent Cases of Chronic Pulmonary Hypertension, Group-specific Prevalent Cases of Chronic Pulmonary Hypertension, Group-specific Prevalent Cases of Chronic Pulmonary Hypertension , and Age-specific Prevalent Cases of Chronic Pulmonary Hypertension in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• The total prevalent cases of Chronic Pulmonary Hypertension in the US are expected to increase with a significant CAGR by 2034, from around 17,910 thousand cases in 2023 in the US.
• Among the European countries, Germany (26%) had the highest prevalent population of Chronic Pulmonary Hypertension, followed by the UK in 2023. On the other hand, Spain had the least diagnosed prevalent population around 15% of Chronic Pulmonary Hypertension in the same year.
• However, the prevalent cases of Chronic Pulmonary Hypertension are expected to decrease in Germany and Japan attributed to decrease in country population and other factors.
• In Japan, among prevalent cases of Chronic Pulmonary Hypertension, most cases were of Group II Chronic Pulmonary Hypertension (~5,724 thousand) in 2023. While least were in Group I Chronic Pulmonary Hypertension around 54 thousand in the same year.
• The Chronic Pulmonary Hypertension prevalent cases were segmented based on age in four age‐groups <45 years, 45-54 years, 55-64 years, 65 years and above. Our estimate suggests that in the US highest number of cases were in the age group 65 years and above (52%) and the least in <45 years (2%) in 2023.
• Assessments as per DelveInsight’s analysts show that the majority of cases of Chronic Pulmonary Hypertension are occupied by females in comparison to males. There were approximately ~6,806 thousand male and ~11,104 thousand female cases of Chronic Pulmonary Hypertension in 2023 in the US.

Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Chronic Pulmonary Hypertension Prevalence

Chronic Pulmonary Hypertension Recent Developments

• In March 2025, SCIENTURE HOLDINGS, INC. announced it completed a draw on its Equity Line of Credit (ELOC) to support the commercial launch of Arbli™ (losartan potassium) Oral Suspension. The company also temporarily suspended further ELOC draws for the next 30 trading days or until its stock reaches $10 per share, whichever comes first.

Chronic Pulmonary Hypertension Drug Chapters

The drug chapter segment of the Chronic Pulmonary Hypertension treatment market report encloses a detailed analysis of Chronic Pulmonary Hypertension marketed drugs and late-stage (Phase-III and Phase-II) Chronic Pulmonary Hypertension pipeline drugs. It also helps to understand the Chronic Pulmonary Hypertension clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Chronic Pulmonary Hypertension Marketed Drugs

• ADEMPAS (riociguat): Bayer

ADEMPAS (riociguat) is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). Riociguat has a dual mode of action. It sensitizes sGC to endogenous NO by stabilizing the NO-sGC binding.

Note: Detailed current therapies assessment will be provided in the full report of Chronic Pulmonary Hypertension ...

Chronic Pulmonary Hypertension Emerging Drugs

• CS1: Cereno Scientific AB

The drug candidate CS1 is a HDAC inhibitor with a new advanced reformulation of valproic acid (VPA) and acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic, and pressure-relieving properties. CS1 is being developed as a treatment for the rare disease PAH with the aim of offering patients a better and safer disease-modifying drug. CS1’s unique efficacy profile fits well with the pathogenetic mechanisms of the rare disease PAH and is believed to be able to address today’s major unmet need for better treatment alternatives.

Note: Detailed emerging therapies assessment will be provided in the final report....

Chronic Pulmonary Hypertension Drugs Market Insights

General measure, supportive therapy, pharmacological treatment and Surgical Treatment are used for treating Chronic Pulmonary Hypertension. The therapeutic intervention is classified into calcium channel blockers (CCBs), endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, prostacyclin analogue, anticoagulants and cardiac glycosides. These are used as the pharmacological treatment for Pulmonary Hypertension.

Chronic Pulmonary Hypertension Market Outlook

Phosphodiesterase-5 (PDE-5) inhibitors such as Sildenafil and Tadalafil are efficient in providing the antiproliferative effects on vascular smooth muscle cells and inducing vasodilation. Endothelin receptor antagonists such as Ambrisentan, Bosentan and Macitentan exertvasoconstrictor and mitogenic effects on the pulmonary vascular smooth muscles. Nifedipine, diltiazem, or amlodipine are the most commonly recommended calcium channel blockers being used for the treatment of Pulmonary Arterial Hypertension. Prostacyclins such as epoprostenol, treprostinil, iloprost are recommended for improving the functional capacity and survival rate among the patients of Pulmonary Hypertension.

Apart from the aforesaid, IP prostacyclin receptor agonists are also used in the treatment of Chronic PH. They bind selectively to the IP receptor and follow the prostacyclin pathway. Endothelin Receptor Antagonists helps in bringing down the elevated levels of endothelin-1 that causes constriction and structural changes to the pulmonary blood vessels in PAH patients.

Phosphodiesterase Type 5 (PDE-5) Inhibitors and Guanylate Cyclase (sGC) Stimulators have shown to reduce levels of the enzyme responsible for producing NO, a naturally occurring substance in the body that causes relaxation of the pulmonary blood vessels. NO increases intracellular levels of cyclic guanosine monophosphate GMP (cyclic GMP). Therefore, another established therapeutic approach has been to inhibit the degradation of cyclic GMP using drugs known as PDE-5 inhibitors. In addition, sGC is an enzyme found in the endothelial cells and the receptor for NO. When NO binds to sGC, the enzyme enhances production of cyclic GMP. As a result, sGC stimulators are also approved to treat PAH.

Cereno Scientific’s lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). A clinical phase II study program for CS1 in PAH is planned to start mid-2021 under its US FDA granted orphan drug designation (ODD) status. When the US FDA granted the Orphan Drug Designation for CS1 in Pulmonary Arterial Hypertension, Cereno Scientific opened a door to new possibilities and attractive opportunities. Now, the company has decided to refocus its development efforts for its lead candidate CS1 to rare disease PAH, which they say will optimize the opportunities for the company as well as its shareholders.

It is important to note that there is a need for newer novel therapies for the Chronic Pulmonary Hypertension treatment.

• The total Chronic Pulmonary Hypertension Market Size in the 7MM was approximately USD 28,290 million in 2023 and is projected to increase during the forecast period (2024-2034).
• The Chronic Pulmonary Hypertension Market Size in the 7MM will increase at a constant CAGR due to increasing awareness of the disease, better diagnosis, and the launch of the emerging target therapy for Chronic Pulmonary Hypertension.
• Among EU4 and the UK, Germany with a share of 26% accounted for the maximum Chronic Pulmonary Hypertension Market Size in 2023 while Spain occupied the bottom of the ladder with a share of 15% in 2023.
• In 2023, Japan held the second-largest share, approximately 12%, of the Chronic Pulmonary Hypertension treatment market among the seven major markets (7MM).

Chronic Pulmonary Hypertension Drugs Uptake

This section focuses on the rate of uptake of the potential Chronic Pulmonary Hypertension drugs expected to get launched in the market during the study period 2020-2034. For example, for CS1, we expect the drug uptake to be medium with a probability-adjusted peak share of around 4.2%, and years to the peak is expected to be 4 years from the year of launch in the US.

Further detailed analysis of emerging therapies drug uptake in the report….

Chronic Pulmonary Hypertension Pipeline Development Activities

The Chronic Pulmonary Hypertension therapeutics market report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key Chronic Pulmonary Hypertension Companies involved in developing targeted therapeutics.

Pipeline Development Activities

The Chronic Pulmonary Hypertension therapeutics market report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for Chronic Pulmonary Hypertension emerging therapies.

Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ Chronic Thromboembolic Pulmonary Hypertension Treatment Drugs

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Chronic Pulmonary Hypertension evolving treatment landscape, patient reliance on conventional therapies, patient’s therapy switching acceptability, and drug uptake along with challenges related to accessibility, include Women’s Guild Lung Institute, the United States; Claude Bernard University, France; Graduate School of Medicine, Japan; Caro Research Institute, the United States, and others.

Delveinsight’s analysts connected with 50+ KOLs to gather insights, however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Chronic Pulmonary Hypertension market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and Chronic Pulmonary Hypertension Therapeutics Market Intelligence analysis using various approaches, such as SWOT analysis, and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis is done to analyze multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Chronic Pulmonary Hypertension Therapeutics Market Access and Reimbursement

Reimbursement is a crucial point for any drug after its approval. Many Chronic Pulmonary Hypertension Drugs or therapies are not properly recognized by the reimbursement body and may fail to get reimbursed or their reimbursement process gets delayed. The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Chronic Pulmonary Hypertension Treatment Market Report Scope

• The Chronic Pulmonary Hypertension treatment market report covers a segment of key events, an executive summary, descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression along with treatment guidelines
• Additionally, an all-inclusive account of both the current and emerging therapies along with the elaborative profiles of late-stage and prominent therapies will have an impact on the current Chronic Pulmonary Hypertension treatment market landscape
• A detailed review of the Chronic Pulmonary Hypertension treatment market; historical and forecasted Chronic Pulmonary Hypertension treatment market size, Chronic Pulmonary Hypertension market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach
• The Chronic Pulmonary Hypertension treatment market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preference that help in shaping and driving the 7MM Chronic Pulmonary Hypertension drugs market

Chronic Pulmonary Hypertension Treatment Market Report Insights

• Patient-based Chronic Pulmonary Hypertension Market Forecasting
• Therapeutic Approaches
• Chronic Pulmonary Hypertension Pipeline Analysis
• Chronic Pulmonary Hypertension Market Size and Trends
• Existing and future Chronic Pulmonary Hypertension Therapeutics Market Opportunity

Chronic Pulmonary Hypertension Treatment Market Report Key Strengths

• 11 Years Chronic Pulmonary Hypertension Market Forecast
• 7MM Coverage
• Chronic Pulmonary Hypertension Epidemiology Segmentation
• Key Cross Competition
• Attribute analysis
• Drugs Uptake and Key Chronic Pulmonary Hypertension Market Forecast Assumptions

Chronic Pulmonary Hypertension Treatment Market Report Assessment

• Current Chronic Pulmonary Hypertension Treatment Market Practices
• Chronic Pulmonary Hypertension Unmet Needs
• Chronic Pulmonary Hypertension Pipeline Product Profiles
• Chronic Pulmonary Hypertension Drugs Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions

Chronic Pulmonary Hypertension Treatment Market Insights:

• What was the Chronic Pulmonary Hypertension market size, the Chronic Pulmonary Hypertension treatment market size by therapies, and market share (%) distribution in 2020, and how it would all look in 2034? What are the contributing factors for this growth?
• What are the unmet needs are associated with the current Chronic Pulmonary Hypertension treatment market?
• How is CS1 going to contribute to the Chronic Pulmonary Hypertension treatment market after approval?
• Which drug is going to be the largest contributor in 2034?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Chronic Pulmonary Hypertension Epidemiology Insights:

• What are the disease risk, burden, and Chronic Pulmonary Hypertension unmet needs? What will be the growth opportunities across the 7MM concerning the patient population of Chronic Pulmonary Hypertension?
• What is the historical and forecasted Chronic Pulmonary Hypertension patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis? Why is the current year diagnosis rate not high?
• What factors are affecting the diagnosis and treatment of the indication?

Current Chronic Pulmonary Hypertension Treatment Market Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the Chronic Pulmonary Hypertension Treatment? What are the current treatment guidelines for the treatment of Chronic Pulmonary Hypertension in the US and Europe?
• How many companies are developing therapies for the Chronic Pulmonary Hypertension treatment?
• How many emerging therapies are in the mid-stage and late stage of development for the Chronic Pulmonary Hypertension treatment?
• What are the recent novel therapies, targets, Chronic Pulmonary Hypertension mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the key designations that have been granted for the emerging therapies for Chronic Pulmonary Hypertension?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted Chronic Pulmonary Hypertension Drugs Market?

Reasons to Buy

• The Chronic Pulmonary Hypertension treatment market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Chronic Pulmonary Hypertension Drugs Market
• Insights on patient burden/disease Chronic Pulmonary Hypertension prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• To understand the existing Chronic Pulmonary Hypertension treatment market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the Chronic Pulmonary Hypertension treatment market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the Conjoint analysis section to provide visibility around leading classes
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs
• To understand the perspective of Key Opinion Leaders’ around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in future
• Detailed insights on the unmet need of the existing Chronic Pulmonary Hypertension treatment market so that the upcoming players can strengthen their development and launch strategy

Stay Updated with us for Recent Articles

• Nascent Advancements and Emerging Therapies in Chronic Pulmonary Hypertension Treatment Market
• Chronic Pulmonary Hypertension Market: Infographics
• Pulmonary Arterial Hypertension Newsletter
• Latest DelveInsight Blogs